It is generally accepted that COVID-19 patients rarely exhibit clinical signs of ocular involvement, a finding that may be explained by the reported low expression of SARS-CoV-2 entry sites including ACE2 and TMPRSS16. The gene discussed is ACE2; the disease is COVID-19.